Blanket Purchase Agreement 36F79724D0191-36E79724A0032

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Vanda Pharmaceuticals Inc. (Vanda) on September 6, 2024. The BPA has a ceiling value of $3,753,465.00 and a period of performance through September 5, 2025.

The primary product being procured under this BPA is Hetlioz (tasimelteon), a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome. Vanda, a for-profit organization and manufacturer of goods, has established itself as a key supplier of this specialized pharmaceutical product to the VA. The BPA streamlines the ordering process for VA agencies, ensuring consistent availability of Hetlioz for eligible veterans. This award is not designated as a set-aside and represents a single-award contract. Vanda also holds a multiple-award Federal Supply Schedule contract with the VA, further demonstrating its role as a critical supplier of drugs, pharmaceuticals, and hematology-related products to the federal government.